At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 140 enrolled
Drug / intervention
Aripiprazole Lauroxildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
In Brief
A Phase 1 clinical trial evaluating Aripiprazole Lauroxil for Schizophrenia. Completed, enrolled 140 participants across 16 sites.
Detailed Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedDec 2014
Primary CompletionApr 2016
TodayJul 2026
First PostedDec 19, 2014
Enrollment StartDec 1, 2014
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.5 years ago
Interventions
Aripiprazole Lauroxildrug
Gluteal IM injection, given once every 4 to 8 weeks